

Altered branched-chain α -keto acid metabolism is a feature of NAFLD in individuals with severe obesity

Thomas Grenier-Larouche, Lydia Coulter Kwee, Yann Deleze, Paola Leon-Mimila, Jacquelyn M. Walejko, Robert W. McGarrah, Simon Marceau, Sylvain Trahan, Christine Racine, André C. Carpentier, Aldons J. Lusi, Olga Ilkayeva, Marie-Claude Vohl, Adriana Huertas-Vazquez, André Tchernof, Svati H. Shah, Christopher B. Newgard, Phillip J. White

JCI Insight. 2022;7(15):e159204. <https://doi.org/10.1172/jci.insight.159204>.

Research Article

Hepatology

Metabolism

Hepatic de novo lipogenesis is influenced by the branched-chain α -keto acid dehydrogenase (BCKDH) kinase (BCKDK). Here, we aimed to determine whether circulating levels of the immediate substrates of BCKDH, the branched-chain α -keto acids (BCKAs), and hepatic *BCKDK* expression are associated with the presence and severity of nonalcoholic fatty liver disease (NAFLD). Eighty metabolites (3 BCKAs, 14 amino acids, 43 acylcarnitines, 20 ceramides) were quantified in plasma from 288 patients with bariatric surgery with severe obesity and scored liver biopsy samples. Metabolite principal component analysis factors, BCKAs, branched-chain amino acids (BCAAs), and the BCKA/BCAA ratio were tested for associations with steatosis grade and presence of nonalcoholic steatohepatitis (NASH). Of all analytes tested, only the Val-derived BCKA, α -keto-isovalerate, and the BCKA/BCAA ratio were associated with both steatosis grade and NASH. Gene expression analysis in liver samples from 2 independent bariatric surgery cohorts showed that hepatic *BCKDK* mRNA expression correlates with steatosis, ballooning, and levels of the lipogenic transcription factor *SREBP1*. Experiments in AML12 hepatocytes showed that *SREBP1* inhibition lowered *BCKDK* mRNA expression. These findings demonstrate that higher plasma levels of BCKA and hepatic expression of *BCKDK* are features of human NAFLD/NASH and identify *SREBP1* as a transcriptional regulator of *BCKDK*.

Find the latest version:

<https://jci.me/159204/pdf>



Altered branched-chain α -keto acid metabolism is a feature of NAFLD in individuals with severe obesity

Thomas Grenier-Larouche,^{1,2,3} Lydia Coulter Kwee,¹ Yann Deleye,¹ Paola Leon-Mimila,^{4,5} Jacquelyn M. Walejko,¹ Robert W. McGarrah,¹ Simon Marceau,² Sylvain Trahan,² Christine Racine,² André C. Carpentier,³ Aldons J. Lusis,⁴ Olga Ilkayeva,¹ Marie-Claude Vohl,⁶ Adriana Huertas-Vazquez,⁴ André Tchernof,² Svati H. Shah,¹ Christopher B. Newgard,¹ and Phillip J. White¹

¹Sarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Divisions of Endocrinology and Cardiology, Department of Medicine, and Department of Pharmacology and Cancer Biology, Durham, North Carolina, USA. ²Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada. ³Faculty of Medicine and Health Sciences, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada. ⁴Department of Medicine/Division of Cardiology, UCLA, California, USA. ⁵Facultad de Química, Universidad Nacional Autónoma de México/Instituto Nacional de Medicina Genómica, Unidad de Genómica de Poblaciones Aplicada a la Salud, Mexico City, Mexico. ⁶Centre de Nutrition, Santé et Société and Institute of Nutrition and Functional Foods, Université Laval, Quebec City, Quebec, Canada.

Authorship note: TGL and LCK are co-first authors.

Conflict of interest: PJW, TGL, and CBN have filed a patent application related to the use of BCKA and the BCKA/BCAA ratio as biomarkers for NAFLD and NASH (US20210349103A1). CBN is a member of the Eli Lilly Global Diabetes Advisory Board. AT receives funding from Johnson & Johnson, Medtronic, and GI Windows for studies on bariatric surgery and has acted as a consultant for Bausch Health, Novo Nordisk, and BioTwin.

Copyright: © 2022, Grenier-Larouche et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Submitted: February 8, 2022

Accepted: July 6, 2022

Published: August 8, 2022

Reference information: *JCI Insight*. 2022;7(15):e159204.
<https://doi.org/10.1172/jci.insight.159204>.

Hepatic de novo lipogenesis is influenced by the branched-chain α -keto acid dehydrogenase (BCKDH) kinase (BCKDK). Here, we aimed to determine whether circulating levels of the immediate substrates of BCKDH, the branched-chain α -keto acids (BCKAs), and hepatic *BCKDK* expression are associated with the presence and severity of nonalcoholic fatty liver disease (NAFLD). Eighty metabolites (3 BCKAs, 14 amino acids, 43 acylcarnitines, 20 ceramides) were quantified in plasma from 288 patients with bariatric surgery with severe obesity and scored liver biopsy samples. Metabolite principal component analysis factors, BCKAs, branched-chain amino acids (BCAAs), and the BCKA/BCAA ratio were tested for associations with steatosis grade and presence of nonalcoholic steatohepatitis (NASH). Of all analytes tested, only the Val-derived BCKA, α -keto-isovalerate, and the BCKA/BCAA ratio were associated with both steatosis grade and NASH. Gene expression analysis in liver samples from 2 independent bariatric surgery cohorts showed that hepatic *BCKDK* mRNA expression correlates with steatosis, ballooning, and levels of the lipogenic transcription factor *SREBP1*. Experiments in AML12 hepatocytes showed that *SREBP1* inhibition lowered *BCKDK* mRNA expression. These findings demonstrate that higher plasma levels of BCKA and hepatic expression of *BCKDK* are features of human NAFLD/NASH and identify *SREBP1* as a transcriptional regulator of *BCKDK*.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is characterized by neutral lipid accumulation in the liver. In approximately 1 of every 5 cases, this is accompanied by pathologic inflammation and hepatocellular damage (ballooning), termed nonalcoholic steatohepatitis (NASH) (1). This more pathogenic form of NAFLD progresses to fibrosis in approximately 35% of patients, significantly raising the risk for development of hepatocellular carcinoma, cirrhosis, and acute liver failure. Advanced NAFLD is also a significant risk factor for development of type 2 diabetes and cardiovascular diseases (2, 3).

There has been a sharp increase in the incidence of NAFLD in recent years due to the obesity pandemic; this has resulted in 25% of the US population having a diagnosis of NAFLD. The incidence of NAFLD-related liver failure is now comparable to hepatitis C as a primary reason necessitating liver transplantation (4). An individual's propensity for developing NAFLD is dictated by a combination of genetics, lifestyle, diet, and insulin sensitivity (5, 6). Hepatic triglyceride pools are influenced by supply of adipose-derived nonesterified fatty acids (NEFAs) to the liver, hepatic de novo lipogenesis (DNL), NEFA

export in VLDLs, and hepatic rates of β oxidation and ketogenesis. Importantly, metabolic flux studies show that high compared with low hepatic fat content in otherwise well-matched study participants with obesity is associated with 3-fold higher rates of DNL but no difference in adipose efflux of NEFAs or production of VLDLs (7). Thus, hepatic DNL appears to be one important distinguishing feature of NAFLD status in the setting of obesity. Coupling of β oxidation to the TCA cycle rather than ketogenesis may also be an underlying feature of people with NAFLD (8), although this has yet to be studied in a population that is well matched for obesity but discordant for NAFLD.

Our prior work identified a new function for the branched-chain α -keto acid dehydrogenase (BCKDH) kinase (BCKDK) and protein phosphatase, Mg^{2+}/Mn^{2+} -dependent 1K (PPM1K) as posttranslational regulators of ATP citrate lyase (ACLY), a key enzyme involved in hepatic DNL (9, 10). Whereas phosphorylation of BCKDH by BCKDK is inhibitory and promotes accumulation of branched-chain α -keto acids (BCKAs) and their cognate branched-chain amino acids (BCAAs) in plasma (9), phosphorylation of ACLY is activating and results in increased DNL via production of cytosolic acetyl CoA, which leads to the formation of the immediate DNL precursor and inhibitor of fatty acid oxidation, malonyl CoA (11, 12). Hepatic BCKDK levels are elevated in genetic models of obesity and following ingestion of diets high in fructose in rats, whereas PPM1K levels are low in these settings and increased during fasting (9, 10). Feeding of diets high in fructose induces expression of the lipogenic transcription factor carbohydrate responsive–element binding protein- β (ChREBP- β), and ChREBP- β overexpression is sufficient to increase *BCKDK* and decrease *PPM1K* expression in rat liver (9). In addition, adenovirus-mediated overexpression of recombinant BCKDK increases phosphorylation of ACLY and raises DNL by 2.5-fold in lean healthy rats (9). Conversely, inhibition of BCKDK with a small molecule, BT2, or adenovirus-mediated overexpression of recombinant PPM1K in livers of obese Zucker fatty rats lowers hepatic triglyceride content by more than 40% (9). These effects occur within 7 days of BCKDK inhibition or PPM1K overexpression, in the absence of changes in food intake or body weight, alongside robust lowering of circulating BCKA (9). We also found an association between hepatic *BCKDK* and *ChREBP β* expression in liver samples from humans with NASH (9), but the relationship of the metabolites directly regulated by this axis (i.e., BCKA) to NAFLD has not been examined.

Thus, we postulated that circulating levels of BCKAs correlate with NAFLD status in people with obesity. We tested and validated this hypothesis in a well-characterized cohort of 288 bariatric surgery patients with severe obesity (BMI, >35 kg/m²) from the Quebec Heart and Lung Institute (QHLI) Obesity Biobank, from whom liver biopsies were also taken at the time of bariatric surgery for histological grading of steatosis, inflammation, ballooning, and fibrosis. We also examined associations of hepatic *BCKDK* mRNA expression with hepatic steatosis, ballooning, and inflammation in 2 independent bariatric surgery cohorts. These studies highlighted a possibly novel relationship between *BCKDK* and the lipogenic transcription factor sterol regulatory–element binding protein-1 (SREBP1) that was subsequently explored in vitro.

Results

Characteristics of the metabolite study population. To test our hypothesis that circulating levels of BCKAs are associated with NAFLD status in people with obesity we performed targeted metabolomic analysis in plasma samples from 288 bariatric surgery patients with severe obesity (BMI >35 kg/m²) from the QHLI Obesity Biobank; liver biopsies were also taken from these patients at the time of bariatric surgery for histological grading of steatosis, inflammation, ballooning, and fibrosis. Demographic and clinical information for the study population are provided in Table 1. The metabolite study population from the QHLI Obesity Biobank allowed for stratification by steatosis grade or NASH status among participants otherwise closely matched for age, sex, and BMI. With regards to clinical features associated with steatosis, we observed an increased prevalence of NASH and fibrosis in participants with more severe steatosis. We also genotyped participants for the presence of the patatin-like phospholipase domain-containing protein 3 (*PNPLA3*) Ile148Met variant, previously shown to be commonly associated with elevated liver fat in Mexican American individuals (13). At least 1 copy of the Ile148Met variant, or G allele, was present in 48% of the patients studied here. Consistent with prior reports in Mexican American individuals (13), the *PNPLA3* Ile147Met variant was more common in French Canadian individuals with higher steatosis grade; 27% of participants with a steatosis grade of 0 had at least 1 copy of this variant versus 78% of participants with a steatosis grade of 3. Steatosis grade was also associated with impaired fasting glucose, HbA1c, insulin, and fasting plasma glucose levels. No association was found between steatosis grade and the proportion of individuals taking medications for

blood pressure or lipids. Steatosis grade was also not associated with total cholesterol, high-density lipoprotein, or low-density lipoprotein cholesterol concentrations, but it was strongly associated with plasma triglycerides and circulating liver enzyme levels (alanine transaminase [ALT], aspartate transaminase [AST], and γ -glutamyltransferase [GGT]).

With regards to the clinical features of NASH, the presence of NASH was associated with more severe steatosis, and individuals with NASH were more likely to have advanced fibrosis (grade 2–4) than those without NASH (38% vs. 13%). Associations between NASH and plasma lipids, liver enzymes, and medications mirrored those for steatosis grade. The *PNPLA3* Ile148Met variant, HbA1c, and fasting plasma glucose were also strongly associated with the presence of NASH.

A BCKA-related signature of NAFLD status. In order to test the association between BCKA and NAFLD status in the broader context of other potentially relevant metabolic pathways, we quantified 80 metabolites in the 288 plasma samples from the QHLI Obesity Biobank. The metabolites measured included the 3 BCKAs, 14 amino acids, 43 acylcarnitines, and 20 ceramides. Principal component analysis (PCA) with varimax rotation was employed for dimensionality reduction of these 80 metabolites, resulting in 18 PCA factors with eigenvalues of more than 1 and explaining 73% of total variance (Supplemental Table 1; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.159204DS1>). We then tested associations of the 3 individual BCKAs (α -keto-isovalerate [KIV], α -keto-isocaproate [KIC], and α -keto- β -methylvalerate [KMV]), the molar sum of BCAA (Val, Ile/Leu), the BCKA/BCAA ratio (molar sum of KIV, KIC, and KMV divided by the molar sum of Val, Ile/Leu), and the 18 PCA factors with steatosis grade, NASH, and the presence of advanced fibrosis using univariate and multivariate regression.

In univariate analyses, only KIV (the BCKA derived from Val) and the standardized BCKA/BCAA ratio were strongly associated with both steatosis grade and NASH (Table 2). Specifically, higher levels of KIV and larger BCKA/BCAA ratios were associated with higher steatosis grade (OR [95% CI], 1.2 [1.1–1.3], $P = 1.1 \times 10^{-4}$ and OR [95% CI], 1.5 [1.2–1.9], $P = 2.9 \times 10^{-4}$, respectively) and increased risk of NASH (OR [95% CI], 1.2 [1.1–1.3], $P = 4.0 \times 10^{-4}$ and OR [95% CI], 2.0 [1.5–2.7], $P = 3.0 \times 10^{-6}$, respectively). This association does not appear to be driven by BCAA, because none of the individual BCAAs or the PCA factor 5 (Supplemental Table 1), which is primarily composed of the 3 BCKAs and their cognate BCAA, displayed an association with steatosis grade or NASH.

Besides KIV and the BCKA/BCAA ratio, no other metabolite or metabolite factor was associated with both steatosis grade and NASH in univariate analysis. Moreover, of the 18 PCA factors listed in Supplemental Table 1, only factor 14 (alanine and proline) and factor 7 (glycine, serine, and histidine) were associated with steatosis grade, whereas factor 10 (C20:4, C22, C18:2-OH acylcarnitines) was the only PCA factor associated with NASH alone (Supplemental Table 1). No metabolites or factors measured in the present study were found to be associated with the presence of advanced fibrosis.

The associations of KIV with steatosis grade and NASH, and the BCKA/BCAA ratio with NASH, were maintained when a multivariate statistical model that considered BMI, sex, age, HbA1c, ALT, AST, GGT, *PNPLA3* Ile148Met genotype, and study batch was applied (Table 2). Similar results were obtained when insulin was used in place of HbA1c (data not shown). However, the associations of BCKA/BCAA ratio with steatosis grade and factor 10 with NASH were somewhat attenuated after adjustment for these clinical variables. To explore this further, we tested for 2-way interactions between sex and *PNPLA3* Ile148Met genotype and these metabolites. The interaction of the BCKA/BCAA ratio with sex was marginally significant ($P = 0.05$); sex-stratified analysis then revealed that BCKA/BCAA was associated with steatosis grade in female participants (OR [95% CI], 1.7 [1.2–2.3], $P = 0.002$), but the association was completely absent in the male cohort (OR [95% CI], 1.0 [0.7–1.5], $P = 0.9$) (Supplemental Figure 1). Similarly, we observed an interaction between factor 10 and the *PNPLA3* Ile148Met variant in the NASH analysis ($P = 0.003$). In stratified analyses, there was no association of factor 10 and NASH in carriers of the *PNPLA3* Ile148Met variant (G allele) (OR [95% CI], 0.8 [0.5–1.4], $P = 0.5$), while participants without a copy of the variant showed an association (OR [95% CI], 0.3 [0.1–0.6], $P = 7 \times 10^{-4}$) (Supplemental Figure 1).

Association of hepatic BCKDK mRNA expression with features of NASH in people with severe obesity. We next explored the relationship between *BCKDK* mRNA expression in hepatic tissue and the individual features of NASH, using liver biopsies from a smaller cohort of 60 bariatric surgery patients with severe obesity from the QHLI Obesity Biobank, as well as existing transcriptomics data from 107 bariatric surgery patients with severe obesity from the Mexican Obesity Surgery (MOBES) cohort (Supplemental Table 2). Despite

Table 1. Baseline characteristics of the study population

	Steatosis grade					NASH		
	Grade 0	Grade 1	Grade 2	Grade 3	P	No NASH	NASH	P
n	57	118	58	55		202	74	
Age (yr), mean (SD)	40.8 (10.1)	41.8 (9.9)	41.1 (8.3)	41.2 (9.2)	0.928	40.8 (9.8)	42.2 (8.9)	0.273
Male, n (%)	17 (29.8)	42 (35.6)	19 (32.8)	19 (34.5)	0.893	68 (33.7)	25 (33.8)	0.99
Female, n (%)	40 (70.2)	76 (64.4)	39 (67.2)	36 (65.5)		134 (66.3)	49 (66.2)	
Body mass index (kg/m ²), mean (SD)	48.9 (6.9)	49.3 (5.0)	49.4 (6.0)	50.4 (6.3)	0.564	49.2 (5.8)	50.2 (6.1)	0.181
Steatosis grade								<0.001
0						56 (27.7)	0 (0)	
1						99 (49.0)	14 (18.9)	
2						31 (15.3)	25 (33.8)	
3						16 (7.9)	35 (47.3)	
NASH, n (%)	0 (0)	14 (11.8)	26 (44.8)	35 (63.6)	<0.001			
Fibrosis ^A (grades 2–4), n (%)	2 (3.5)	23 (19.5)	10 (17.2)	22 (40.7)	<0.001	27 (13.4)	28 (37.8)	0.007
Copies of <i>PNPLA3</i> Ile148Met variant					<0.001			0.021
0, n (%)	40 (72.7)	64 (54.7)	26 (47.3)	12 (21.8)		115 (57.8)	27 (37.0)	
1, n (%)	13 (23.6)	44 (37.6)	24 (43.6)	36 (65.5)		71 (35.7)	37 (50.7)	
2, n (%)	2 (3.6)	9 (7.7)	5 (9.1)	7 (12.7)		13 (6.5)	9 (12.3)	
Impaired fasting glucose, n (%)	8 (14.0)	24 (20.3)	19 (32.8)	21 (38.2)	0.007	47 (23.3)	22 (29.7)	0.346
HbA1C (%), mean (SD)	5.5 (0.4)	5.6 (0.4)	5.7 (0.4)	5.8 (0.4)	0.003	5.6 (0.4)	5.7 (0.3)	0.04
Insulin (pmol/L) ^B , mean (SD)	139 (72)	197 (153)	196 (105)	236 (87)	0.008	182.9 (132.7)	223.6 (76.8)	
Fasting plasma glucose (mg/dL), mean (SD)	97.9 (9.7)	101.6 (11.1)	102.9 (11.4)	104.4 (9.7)	0.009	100.4 (10.8)	105.2 (9.9)	0.001
Taking blood pressure medications, n (%)	18 (31.6)	38 (32.2)	25 (43.1)	12 (21.8)	0.118	63 (31.2)	29 (39.2)	0.269
Taking lipid-lowering medications, n (%)	8 (14.0)	13 (11.0)	9 (15.5)	5 (9.1)	0.699	29 (14.4)	6 (8.1)	0.239
Total cholesterol (mg/dL), mean (SD)	177.9 (29.2)	180.1 (31.4)	184.3 (34.4)	183.1 (28.2)	0.669	179.5 (32.0)	185.2 (29.1)	0.18
High-density lipoprotein (mg/dL), mean (SD)	51.0 (13.1)	47.8 (10.2)	48.0 (11.1)	49.6 (17.8)	0.407	48.4 (11.4)	48.6 (15.0)	0.922
Low-density lipoprotein (mg/dL), mean (SD)	105.1 (28.8)	106.3 (29.2)	103.9 (29.3)	104.1 (29.4)	0.945	104.9 (30.1)	106.8 (27.7)	0.626
Triglycerides (mg/dL), mean (SD)	110.4 (45.4)	131.3 (52.5)	166.1 (78.9)	159.2 (75.5)	<0.001	132.0 (60.6)	159.6 (67.6)	0.001
ALT (U/L), mean (SD)	24.1 (26.3)	29.4 (16.1)	35.3 (18.0)	41.0 (17.1)	<0.001	28.6 (19.9)	40.8 (17.7)	<0.001
AST (U/L), mean (SD)	20.0 (13.4)	22.7 (11.2)	25.6 (9.6)	29.7 (9.4)	<0.001	22.2 (11.5)	29.0 (9.4)	<0.001
GGT (U/L), mean (SD)	24.9 (25.5)	28.6 (14.5)	46.6 (55.8)	41.1 (19.7)	<0.001	30.1 (22.9)	44.8 (46.7)	

Continuous variables are presented as mean (SD), with *P* values from 1-way ANOVA (steatosis grade) or *t* tests (NASH). Categorical variables are presented as *n* (%), with *P* values from χ^2 tests for both phenotypes. NASH, nonalcoholic steatohepatitis; ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ -glutamyltransferase. ^AData are missing for *n* = 2 participants. ^BData are missing for *n* = 73 participants.

the potential environmental differences and differences in ethnicity present among the French Canadian and Mexican cohorts, the relationships between hepatic *BCKDK* mRNA expression and features of NASH were remarkably similar (Table 3). Results from both cohorts were consistent with the strong associations observed for KIV BCKA/BCAA ratio with steatosis and NASH, showing significant positive associations between hepatic *BCKDK* gene expression and steatosis grade, ballooning, and NASH. There was no association between *BCKDK* expression and lobular inflammation in either cohort.

The lipogenic transcription factor SREBP1 regulates BCKDK mRNA expression. Our prior work identified the fructose-sensing lipogenic transcription factor, ChREBP, as a mechanism linking *BCKDK* to the lipogenic process (9). In line with this prior observation, we observed a positive association between the *ChREBP* α and *BCKDK* transcript levels in the sequencing data from the MOBES cohort ($R = 0.33$, $P = 6.4 \times 10^{-5}$). In light of our observation of a strong association of circulating BCKA and hepatic *BCKDK* expression with NAFLD/NASH in people with severe obesity we aimed to determine whether another major lipogenic transcription factor, SREBP1 might also regulate hepatic *BCKDK* gene expression. Examination of SREBP1 ChIP-Seq data and histone acetylation patterns surrounding the *BCKDK* locus in HEPG2 cells in the ENCODE database (<https://www.encodeproject.org/>) revealed that SREBP1 peaks are present in both the *BCKDK* promoter and the enhancer region upstream of the *BCKDK* gene where ChREBP was previously found to bind (Figure 1A). Sequence alignment data show that, in contrast to the enhancer region identified as bound by ChREBP that is present in humans and rats but not mice, the promoter

Table 2. Metabolites significantly associated with either steatosis grade or NASH

Phenotype	Metabolite	<i>n</i>	Univariate model		Multivariate model	
			OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Steatosis grade	Factor 14	288	1.52 (1.23–1.89)	1.3×10^{-4}	1.65 (1.31–2.11)	3.6×10^{-5}
	Factor 7	288	0.58 (0.47–0.73)	2.5×10^{-6}	0.59 (0.46–0.75)	2.6×10^{-5}
	KIV	288	1.16 (1.08–1.26)	1.1×10^{-4}	1.16 (1.06–1.26)	8.2×10^{-4}
	BCKA/BCAA	288	1.49 (1.2–1.85)	2.9×10^{-4}	1.34 (1.06–1.7)	0.015 ^A
NASH	BCKA/BCAA	276	2.01 (1.51–2.71)	3.0×10^{-6}	2.15 (1.54–3.06)	1.2×10^{-5}
	KIV	276	1.19 (1.08–1.31)	4.0×10^{-4}	1.27 (1.13–1.44)	1.1×10^{-4}
	Factor 10	276	0.61 (0.45–0.82)	0.0014	0.57 (0.39–0.82))	

^AResult was not significant after Bonferroni's adjustment for multiple tests. OR values of more than 1 indicate that increased levels of the metabolite (or metabolites heavily loaded on the PCA factor) are associated with higher steatosis grade or increased risk of NASH. Multivariate model was adjusted for HbA1c, ALT, AST, GGT, BMI, sex, age, *PNPLA3* genotype, and study phase. NASH, nonalcoholic steatohepatitis; ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ -glutamyltransferase; *PNPLA3*, patatin-like phospholipase domain-containing protein 3; KIV, α -keto isovalerate; BCKA, branched-chain α -keto acids; BCAA, branched-chain amino acids.

region bound by SREBP1 was conserved across all species (Figure 1A). In line with these ChIP-Seq data, examination of the relationship between *SREBP1* and *BCKDK* transcript levels in the RNA-Seq data from the MOBES cohort revealed a robust positive correlation between *SREBP1* and *BCKDK* mRNA expression in human liver ($R = 0.45$, $P = 1.1 \times 10^{-6}$; Figure 1B). We therefore directly tested the regulation of *BCKDK* mRNA expression by SREBP1 in AML12 hepatocytes in vitro using 2 well-validated chemical inhibitors of SREBP1, Betulin (14) and PF-429242 (15). Forty-eight hours after treatment with either Betulin or PF-429242, AML12 hepatocytes displayed significantly lower expression of the SREBP1 target gene, fatty acid synthase (*FASN*), as well as *BCKDK* (Figure 1, C and D). Together, these data place SREBP1 alongside ChREBP as a lipogenic transcriptional regulator of *BCKDK* gene expression. This finding is consistent with the well-established overlap between SREBP1 and ChREBP in the regulation of lipogenic gene expression; however, additional work is warranted to determine whether one of these lipogenic transcription factors exerts a stronger influence on hepatic BCKDK expression or if simultaneous binding of both factors exerts a synergistic effect on hepatic BCKDK induction in liver.

Discussion

Our metabolomic analysis of plasma from a well-characterized population of people with severe obesity revealed that BCKA, KIV, and the BCKA/BCAA ratio were the only metabolite features strongly associated with both steatosis grade and NASH, even after adjustment for multiple covariables. Moreover, we demonstrated that the hepatic expression of *BCKDK* mRNA is strongly associated with steatosis grade, ballooning, and NASH in livers of 2 distinct bariatric surgery populations with severe obesity. These results are consistent with our finding in rats showing that pharmacologic or molecular manipulation of the hepatic BCKDK/PPM1K ratio to favor BCKDK simultaneously increases circulating BCKA levels, via inhibition of BCKDH, and hepatic DNL, via activation of ACLY (9). The current findings expand upon our studies in rodents to implicate this integrative metabolic regulatory node as a potential therapeutic target for human NAFLD. Our studies also introduce SREBP1 as a second lipogenic transcription factor, along with ChREBP- β , in regulation of *BCKDK* gene expression. Finally, our data provide evidence for a potential clinical utility for plasma levels of KIV or the BCKA/BCAA ratio to identify individuals with NAFLD/NASH that might be best suited to therapies that target the lipogenic machinery.

BCAAs have repeatedly emerged as strong biomarkers of cardiometabolic disease traits such as obesity, insulin resistance, and future diabetes development (10, 16–20). More recently, a number of studies have demonstrated an association between BCAA and presence of NAFLD (21–25). Herein, our work suggests that BCKAs are a more sensitive indicator of NAFLD and NASH status than BCAA in people with severe obesity. We propose that this is due to the fact that circulating BCAAs can be affected by a diverse set of metabolic adaptations in the obese milieu, including insulin resistance, dietary changes, altered gut microbiota, and downregulation of components of BCAA catabolism in metabolic tissues

Table 3. Association of hepatic BCKDK mRNA expression with NASH traits

Phenotype	QHLI cohort (n = 60)			MOBES cohort (n = 107)		
	R	P	P ^A	R	P	P ^A
Steatosis	0.29	0.03	0.03	0.34	0.001	0.001
Ballooning	0.42	0.004	0.003	0.44	6.1 × 10 ⁻⁶	7.7 × 10 ⁻⁶
Lob Inflam	0.16	NS	NS	0.15	NS	NS
NASH	0.37	0.01	0.02	0.36	3.0 × 10 ⁻⁴	4.4 × 10 ⁻⁴

^AP values adjusted for age, sex, and BMI. BCKDK, branched-chain α -keto acid dehydrogenase kinase; NASH, nonalcoholic steatohepatitis; QHLI, Quebec Heart and Lung Institute; MOBES, Mexican Obesity Surgery; Lob Inflam, lobular inflammation.

other than liver, such as adipose (10, 26–33). In contrast, the liver does not metabolize BCAA due to very low levels of the branched-chain amino-acid aminotransferase (BCAT) (34), whereas its high levels of BCKDH expression make it one of the most active sites of BCKA catabolism (35, 36). Thus, our data support the notion that measurement of plasma BCKAs or the ratio of BCKA/BCAA, which provides correction for systemic BCAA load, provides a sensitive index of the balance of BCKDK/PPM1K in the liver and NAFLD status.

Although the single BCKA KIV was strongly associated with both steatosis grade and NASH in both univariate and multivariate analyses, the association of the BCKA/BCAA ratio with steatosis grade was attenuated when the multivariate model was applied and, subsequently, determined to be significant only in female participants. This sex interaction may be driven by differences in the partitioning of BCAA. Indeed, levels of BCAA and related metabolites are known to be higher in male than female individuals, as shown in a cohort of adults who are overweight or obese (37) or in pediatric participants with a comparable BMI (38). Moreover, BCAA levels were recently reported to be associated with NAFLD status in women but not in men (24). Moreover, sex-dependent differences in the relationship of BCAA with fasting glucose and lipids have been described in early adolescence (39). One possible mechanism underlying these observations is that the female sex hormone estrogen promotes BCAA uptake by inducing the expression of the cell polarity protein LLGL7L2, which binds to and activates the large neutral amino acid transporter SLC7A5 at the cell surface (40). However, additional work is needed to better understand the differential regulation of BCAA utilization across the sexes and whether this contributes to any differences in risk for NAFLD and/or other cardiometabolic diseases.

Beyond KIV and the BCKA/BCAA ratio, we identified 2 additional amino acid–related factors associated with steatosis grade, as well as a long-chain acylcarnitine-related factor that was associated with the presence of NASH in carriers of the major *PNPLA3* allele. Factors 7 and 14 are made up of glycine-related amino acids (glycine, serine, and histidine) and nitrogen-handling metabolites (alanine and proline), respectively. Importantly, the negative association of glycine and serine with steatosis grade and BCAA levels observed here has also been reported in other cohorts (26, 36, 41–43). Factor 10, composed of C20:4, C22, C18:2 carnitines, was found to associate with the presence of NASH in univariate analysis. Given that the metabolite with strongest loading in this factor is arachidonyl (C20:4) carnitine, it is tempting to speculate that the association between this factor and NASH is driven by arachidonic acid–derived lipid mediators known to play a role in inflammation, such as the leukotrienes and prostaglandins (44).

In conclusion, this study provides proof of concept in humans that the BCKA plasma level or the BCKA/BCAA ratio associates with NAFLD status in obese individuals. This finding also provides support for the idea that excessive hepatic expression of the BCKDK, now understood to also play a role in regulation of the critical DNL enzyme ACLY (9), plays an important role in the development of NAFLD in human obesity. The major strengths of our study include the use of a well-characterized population matched for several confounders across grades of liver steatosis, the use of samples in which liver phenotypes were determined via gold standard histological grading, and validation of gene expression studies across obesity cohorts with different ethnic backgrounds. Future studies are warranted to verify if the associations described herein will be observed in other populations with different ethnic backgrounds and other forms of fatty liver disease.




Figure 1. Regulation of *BCKDK* expression by *SREBP1*. (A) H3K27Ac peaks (multicolored) and SREBP1 ChIP-Seq data (pink) in the promoter and upstream enhancer region of the *BCKDK* gene. Conservation of these genomic regions relative to the human genome is indicated by vertical black hatch marks to the right of each mammal. (B) Correlation between *BCKDK* and *SREBP1* gene expression in liver samples from the Mexican Obesity Surgery cohort. (C and D) The effect of the SREBP1 inhibitors, Betulin and PF-429242, on *FASN* and *BCKDK* mRNA expression in AML12 cells. Data are expressed as the mean \pm SEM of 3 independent experiments. A 1-way ANOVA with a Dunnett's post hoc test was employed to determine statistical significance. **** $P < 0.001$.

Methods

Study participants. The study population employed for plasma metabolomic analysis consisted of a cohort of patients of European ancestry with severe obesity (BMI >35 kg/m²) from the eastern provinces of Canada who underwent bariatric surgery at the Institut universitaire de cardiologie et de pneumologie de Québec (QHLI). Of the patients with available samples at the QHLI Obesity Biobank, 404 met the initial inclusion criteria for the study, which were as follows: HbA1c of less than 6% and fasting plasma glucose of less than 126 mg/dL, histologic NAFLD characterization, consent for genetic studies, and not on diabetes medications. NAFLD was present in 79% of these patients (steatosis grade 1 [5%–33%], 55%; grade 2 [34%–66%], 18%; grade 3 [$>67\%$], 6%). For this study, 288 participants were selected across a range of steatosis grades (grade0–3) and were matched for age, sex, BMI, and glucose tolerance; additionally, participants had steatosis with NASH (defined as the presence of steatosis alongside both lobular inflammation and ballooning) or without NASH. Evaluation of liver histology was performed by a pathologist according to the methods of Brunt et al. (45). Biospecimens were obtained from the biobank of the Institut universitaire de cardiologie et de pneumologie de Québec in accordance with institutionally approved management modalities.

For liver gene expression analyses, a set of liver biopsy specimens from 60 individuals with severe obesity (BMI >35 kg/m²) was obtained from the QHLI Obesity Biobank. Similar to the samples used for metabolomic analysis, samples were from patients of European ancestry from the eastern provinces of Canada with severe obesity who underwent bariatric surgery at the QHLI and were discordant for NAFLD and NASH, as determined by a pathologist according to the methods of Brunt et al. (45). The results from this targeted gene expression analysis were validated using existing transcriptomic data from the MOBES cohort (46–48).

Genotyping. *PNPLA3* genotyping for the Ile148Met variant associated with hepatic steatosis (rs738409) was performed for samples from the QHLI Obesity Biobank on genomic DNA extracted from blood buffy coats using the GenElute Blood Genomic DNA kit (MilliporeSigma). rs738409 was

genotyped using validated primers and TaqMan probes (Applied Biosystems). *PNPLA3* genotypes were determined using 7500 Fast Real-Time PCR System (Applied Biosystems).

Metabolite profiling. BCKA, amino acid, acylcarnitine, and ceramide levels were measured in plasma by targeted metabolomics methods, as previously described (36, 49). Briefly, plasma concentrations of the α -keto acids of Leu (KIC, KMV, and KIV) were measured by LC-MS, and amino acid ($n = 15$), acylcarnitine ($n = 45$), and ceramide ($n = 21$) profiling was performed by tandem mass spectrometry. All MS analyses employed stable isotope dilution with internal standards from Isotec, Cambridge Isotopes Laboratories, and CDN Isotopes.

Gene expression analysis. For the human liver samples from the QHLI Obesity Biobank, PCR was used to measure gene expression. Specifically, total RNA was isolated using the total RNA purification kit (NORGEN BIOTEK). Total RNA for in vitro experiments was isolated using TRI-Reagent (MilliporeSigma, T9424). cDNA was generated using the high-capacity reverse transcription kit (Applied Biosystems), and real-time qPCR was performed on a QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems) using specific primers (Supplemental Table 3) and the PowerUp SYBR Green Master Mix (Applied Biosystems), following the manufacturer's instructions. Gene expression was normalized to RPLP0 using the ddCT method.

RNA-Seq. RNA isolation and sequencing for the MOBES cohort has been described previously (47, 48, 50). Briefly, sequencing was performed using an Illumina HiSeq2500 instrument. After data quality control, sequencing reads were mapped to the human reference genome using TopHat software v2.0.1 (51) and quantified using Cufflinks software (52).

ChIP-Seq analysis in ENCODE. The presence of SREBP1 ChIP peaks near the *BCKDK* transcription start site and previously identified ChREBP binding site upstream of the *BCKDK* gene was assessed using the HEPG2 SREBP1 Standard insulin ChIP-Seq Signal from the ENCODE/SYDH data set, available in the ENCODE project (GEO GSM935627) (53).

AML12 experiments. α Mouse liver cells (ATCC, CRL2254) were cultured in Ham's F-12 (Gibco, ThermoFisher Scientific, 11320033) supplemented with 10% FBS (Gibco, ThermoFisher Scientific, 10437036), 1% glutamine (Gibco, ThermoFisher Scientific, 25030-081), 10 μ g/mL insulin (Gibco, ThermoFisher Scientific, 12585014), 5 μ g/mL transferrin (MilliporeSigma, T1147), 5 ng/mL selenium (MilliporeSigma, S9133), and 40 ng/mL dexamethasone (MilliporeSigma, D4902). They were maintained in a humidified incubator at 37°C under 5% CO₂. Cells were plated in 24-well plates at a density of 80,000 cells/well. The next day, cells were treated with 10 μ M Betulin (Cayman Chemical, 11041) (14), 10 μ M PF-429242 (Cayman Chemical, 15140) (15), or DMSO in complete growth media for 48 hours before harvesting of mRNA in TRI-reagent for gene expression analysis.

Statistics. For the primary study of metabolomics in the samples from the QHLI Obesity Biobank, 80 metabolites met quality control standards and were used in PCA followed by varimax rotation; 18 independent PCA factors with an eigenvalue of more than 1 were retained for subsequent analysis and explained 73% of the total variance. Each PCA factor is described by its primary metabolites ($|\text{loading}| > 0.4$) in Supplemental Table 1. In addition to PCA factors, we considered the 3 individual BCKAs (KIV, KIC, and KMV), BCAAs (Val, Ile/Leu), and the BCKA/BCAA ratio (molar sum of KIV, KIC, KMV/ molar sum of Val, Ile/Leu, standardized to give a quantity with mean = 0 and SD = 1).

Proportional odds logistic regression was employed to test the association of the aforementioned variables with steatosis grade (grade 0, $n = 57$; grade 1, $n = 118$; grade 2, $n = 58$; grade 3, $n = 55$). Logistic regression was used to test the metabolite/PCA factor associations with NASH (yes [$n = 74$]/no [$n = 202$]) and advanced fibrosis (grade 0–1 [$n = 230$] vs. grade 2–4 [$n = 57$]). All associations were tested in both univariate models and multivariate models adjusted for HbA1c, liver enzyme levels (ALT, AST, GGT), BMI, sex, age, *PNPLA3* genotype, and technical batch. Associations were considered significant at $P < 0.0024$, given a Bonferroni adjustment for multiple tests. Metabolites/factors that were significantly associated with a phenotype in univariate, but not multivariate, models were tested for interactions with sex or genotype, followed by stratified analyses as appropriate. Statistical analyses were carried out in R v4.1.2.

For gene expression analyses in both the QHLI cohort and the MOBES cohort, a partial Pearson's correlation analysis corrected for age, sex, and BMI was used to assess the association between *BCKDK* mRNA expression and the individual features of NASH. A nominal $P < 0.05$ was considered significant. Correlation between *BCKDK* and *SREBP1* expression within the MOBES transcriptomics data set was also assessed using a partial Pearson's correlation.

The effects of the SREBP1 inhibitors Betulin and PF-429242 on *BCKDK* and *FASN* mRNA expression in AML12 cells were assessed using 1-way ANOVA with a Dunnett's post hoc test. Data represent 3 independent experiments and are expressed as mean \pm SD. A nominal *P* value of less than 0.05 was considered significant.

Study approval. All studies were conducted according to the principles outlined in the Declaration of Helsinki and approved by the institutional review boards at Université Laval, UCLA, Instituto Nacional de Medicina Genómica, and Duke University. All participants provided written, informed consent.

Author contributions

PJW, TGL, and CBN conceptualized studies. PJW, CBN, SHS, AHV, LCK, YD, PLM, RWM, and TGL interpreted data. PJW, TGL, CBN, SHS, AT, AHV, AJL, RWM, and ACC planned studies. LCK, PLM, JMW, and YD performed statistical analyses. SM, ST, and CR acquired samples. OI conducted metabolomics analyses, MCV performed PNPLA3 genotyping. PLM analyzed sequencing data. YD conducted AML12 studies. PJW wrote the manuscript. CBN, SHS, LCK, TGL, AT, MCV, and PLM edited the manuscript. All authors read and approved the manuscript in its final form. Order of co-first authors was determined by seniority on the project.

Acknowledgments

The authors acknowledge the invaluable collaboration of the surgery team, bariatric surgeons, and biobank staff of the Institut Universitaire de Cardiologie et de Pneumologie de Québec/QHLI and the participants of the studies. We thank Hugo Villamil and Samuel Canizales for sharing MOBES liver gene expression data. This work was supported by an American Diabetes Association Pathways to Stop Diabetes Initiator Award (1-16-INI-17 to PJW) and Cardiovascular-Metabolic Fellowship (1-21-CMF-005 to JMW) as well as NIH grants (DK58398, DK121710, and DK124723 to CBN and HL127009 to SHS), an American Heart Association grant (17SFRN33670990 to SHS), a sponsored research agreement from Pfizer (to CBN), and a Michael Smith Foreign Study Scholarship from the Canadian Institute of Health Research to TGL. MCV is Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Metabolic Health.

Address correspondence to: Phillip J. White, Duke Molecular Physiology Institute, 300 Duke Street, Durham, North Carolina 27701, USA. Phone: 1.919.479.2325; Email: phillip.white@duke.edu.

1. Anstee QM, et al. From NASH to HCC: current concepts and future challenges. *Nat Rev Gastroenterol Hepatol*. 2019;16(7):411–428.
2. Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*. 2017;66(6):1138–1153.
3. Salah HM, et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. *JACC Basic Transl Sci*. 2021;6(11):918–932.
4. Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15(1):11–20.
5. Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med*. 2018;24(7):908–922.
6. White PJ, Abdelmalek MF. Insights into metabolic mechanisms and their application in the treatment of NASH. *Clin Liver Dis (Hoboken)*. 2021;17(1):29–32.
7. Lambert JE, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology*. 2014;146(3):726–735.
8. Fletcher JA, et al. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. *JCI Insight*. 2019;4(11):e127737.
9. White PJ, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. *Cell Metab*. 2018;27(6):1281–1293.
10. White PJ, Newgard CB. Branched-chain amino acids in disease. *Science*. 2019; 363(6427): 582–583.
11. Potapova IA, et al. Phosphorylation of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated Sug. *Biochemistry*. 2000;39(5):1169–1179.
12. Martinez Calejman C, et al. mTORC2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis. *Nat Commun*. 2020;11(1):1–16.
13. Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet*. 2008;40(12):1461–1465.
14. Tang JJ, et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. *Cell Metab*. 2011;13(1):44–56.
15. Hawkins JL, et al. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. *J Pharmacol Exp Ther*. 2008;326(3):801–808.

16. Newgard CB, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* 2009;9(4):311–326.
17. Wang TJ, et al. Metabolite profiles and the risk of developing diabetes. *Nat Med.* 2011;17(4):448–453.
18. Palmer ND, et al. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. *J Clin Endocrinol Metab.* 2015;100(3):E463–E468.
19. Tai ES, et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. *Diabetologia.* 2010;53(4):757–767.
20. Lotta LA, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a mendelian randomisation analysis. *PLoS Med.* 2016;13(11):e1002179.
21. Goffredo M, et al. A branched-chain amino acid-related metabolic signature characterizes obese adolescents with non-alcoholic fatty liver disease. *Nutrients.* 2017;9(7):642.
22. Gaggini M, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. *Hepatology.* 2018;67(1):145–158.
23. van den Berg EH, et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. *Nutrients.* 2019;11(3):705.
24. Grzych G, et al. Plasma BCAA changes in patients with NAFLD are sex dependent. *J Clin Endocrinol Metab.* 2020;105(7):2311–2321.
25. Lischka J, et al. A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity. *Pediatr Obes.* 2021;16(4):e12739.
26. Felig P, et al. Plasma amino acid levels and insulin secretion in obesity. *N Engl J Med.* 1969;281(15):811–816.
27. Mahendran Y, et al. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels. *Diabetologia.* 2017;60(5):873–878.
28. Ridaura VK, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science.* 2013;341(6150):1241214.
29. Pedersen HK, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature.* 2016;535(7612):376–381.
30. Herman MA, et al. Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. *J Biol Chem.* 2010;285(15):11348–11356.
31. She P, et al. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. *Am J Physiol Endocrinol Metab.* 2007;293(6):E1552–E1563.
32. Shin AC, et al. Brain insulin lowers circulating BCAA levels by inducing hepatic BCAA catabolism. *Cell Metab.* 2014;20(5):898–909.
33. Lian K, et al. Impaired adiponectin signaling contributes to disturbed catabolism of branched-chain amino acids in diabetic mice. *Diabetes.* 2015;64(1):49–59.
34. Sweatt AJ, et al. Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. *Am J Physiol Endocrinol Metab.* 2004;286(1):E64–E76.
35. Neinast MD, et al. Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. *Cell Metab.* 2019;29(2):417–429.
36. White PJ, et al. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. *Mol Metab.* 2016;5(7):538–551.
37. Patel MJ, et al. Race and sex differences in small-molecule metabolites and metabolic hormones in overweight and obese adults. *OMICS.* 2013;17(12):627–635.
38. Newbern D, et al. Sex differences in biomarkers associated with insulin resistance in obese adolescents: metabolomic profiling and principal components analysis. *J Clin Endocrinol Metab.* 2014;99(12):4730–4739.
39. Perng W, et al. Branched chain amino acids, androgen hormones, and metabolic risk across early adolescence: a prospective study in project viva. *Obesity (Silver Spring).* 2018;26(5):916–926.
40. Saito Y, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER⁺ breast cancer. *Nature.* 2019;569(7755):275–279.
41. Mardinoglu A, et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. *Nat Commun.* 2014;5(1):3083.
42. Mardinoglu A, et al. Personal model-assisted identification of NAD⁺ and glutathione metabolism as intervention target in NAFLD. *Mol Syst Biol.* 2017;13(3):916.
43. White PJ, et al. Muscle-liver trafficking of BCAA-derived nitrogen underlies obesity-related glycine depletion. *Cell Rep.* 2020;33(6):108375.
44. Innes JK, Calder PC. Omega-6 fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids.* 2018;132:41–48.
45. Brunt EM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol.* 1999;94(9):2467–2474.
46. Chella Krishnan K, et al. Liver pyruvate kinase promotes NAFLD/NASH in both mice and humans in a sex-specific manner. *Cell Mol Gastroenterol Hepatol.* 2021;11(2):389–406.
47. Hui ST, et al. The genetic architecture of diet-induced hepatic fibrosis in mice. *Hepatology.* 2018;68(6):2182–2196.
48. Xiong X, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. *Mol Cell.* 2019;75(3):644–660.
49. Stöckli J, et al. Metabolomic analysis of insulin resistance across different mouse strains and diets. *J Biol Chem.* 2017;292(47):19135–19145.
50. León-Mimila P, et al. Genome-wide association study identifies a functional *SIDT2* variant associated with HDL-C (high-density lipoprotein cholesterol) levels and premature coronary artery Disease. *Arterioscler Thromb Vasc Biol.* 2021;41(9):2494–2508.
51. Kim D, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol.* 2013;14(4):R36.
52. Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol.* 2010;28(5):511–515.
53. Gerstein MB, et al. Architecture of the human regulatory network derived from ENCODE data. *Nature.* 2012;489(7414):91–100.